Payment overview · 2025
General Payments
$1,200.51
81 reported records · 16 companies
Healthcare provider profile · identity verified
David A Oneill, DO
Allopathic & Osteopathic Physicians|Family Medicine · BELLEVILLE, IL · NPI 1922092394
Verified facts
What the public records show
CMS Open Payments records show David A Oneill, DO received $1,200.51 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $321.25 | 26.8% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.98 | 14.6% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.98 | 14.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $157.57 | 13.1% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $80.34 | 6.7% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$50.67 | 4.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $37.83 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.18 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.37 | 2.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.16 | 2.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.19 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.71 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.37 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.73 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.59 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.59 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,200.51 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $174.98 | 19 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $174.98 | 19 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $161.62 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $146.18 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $146.18 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.53 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.53 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $95.37 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $80.34 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.26 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $60.65 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.84 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $50.67 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.04 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.37 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 209 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
209 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 956 | 294 |
| Amlodipine Besylate | Amlodipine Besylate | 932 | 313 |
| Levothyroxine Sodium | Levothyroxine Sodium | 727 | 204 |
| Losartan Potassium | Losartan Potassium | 638 | 197 |
| Metoprolol Succinate | Metoprolol Succinate | 539 | 158 |
| Montelukast Sodium | Montelukast Sodium | 457 | 142 |
| Tramadol Hcl | Tramadol Hcl | 427 | 104 |
| Omeprazole | Omeprazole | 416 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 404 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 142 |
| Alprazolam | Alprazolam | 383 | 81 |
| Gabapentin | Gabapentin | 380 | 102 |
| Lisinopril | Lisinopril | 356 | 119 |
| Sertraline Hcl | Sertraline Hcl | 354 | 92 |
| Metformin Hcl | Metformin Hcl | 348 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 90 |
| Simvastatin | Simvastatin | 284 | 88 |
| Furosemide | Furosemide | 273 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 246 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 86 |
| Lorazepam | Lorazepam | 237 | 48 |
| Buspirone Hcl | Buspirone Hcl | 222 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 73 |
| Glimepiride | Glimepiride | 213 | 68 |
| Ozempic | Semaglutide | 209 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 209 | 64 |
| Azithromycin | Azithromycin | 202 | 155 |
| Eliquis | Apixaban | 199 | 41 |
| Meloxicam | Meloxicam | 198 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 63 |
| Trazodone Hcl | Trazodone Hcl | 192 | 62 |
| Potassium Chloride | Potassium Chloride | 181 | 64 |
| Allopurinol | Allopurinol | 179 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 53 |
| Prednisone | Prednisone | 156 | 83 |
| Ezetimibe | Ezetimibe | 146 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 46 |
| Famotidine | Famotidine | 138 | 56 |
| Carvedilol | Carvedilol | 133 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 47 |
| Clonidine Hcl | Clonidine Hcl | 121 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 41 |
| Bupropion Xl | Bupropion Hcl | 112 | 30 |
| Eszopiclone | Eszopiclone | 110 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 27 |
| Metformin Hcl Er | Metformin Hcl | 99 | 36 |
| Atenolol | Atenolol | 89 | 28 |
| Farxiga | Dapagliflozin Propanediol | 86 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 26 |
| Xarelto | Rivaroxaban | 79 | 20 |
| Clonazepam | Clonazepam | 77 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 49 |
| Finasteride | Finasteride | 73 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 23 |
| Memantine Hcl | Memantine Hcl | 65 | 14 |
| Donepezil Hcl | Donepezil Hcl | 62 | 21 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 51 |
| Sucralfate | Sucralfate | 57 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 18 |
| Pregabalin | Pregabalin | 55 | 15 |
| Jardiance | Empagliflozin | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 20 |
| Alendronate Sodium | Alendronate Sodium | 51 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 30 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 20 |
| Mupirocin | Mupirocin | 49 | 33 |
| Spironolactone | Spironolactone | 48 | 24 |
| Meclizine Hcl | Meclizine Hcl | 47 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 29 |
| Celecoxib | Celecoxib | 43 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 43 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 13 |
| Clonidine | Clonidine | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 13 |
| Cefadroxil | Cefadroxil | 38 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Diazepam | Diazepam | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | 13 |
| Levofloxacin | Levofloxacin | 32 | 30 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 19 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 19 |
| Ondansetron Odt | Ondansetron | 23 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 14 |
| Metronidazole | Metronidazole | 19 | 18 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,200.51 · 81 records | ABBVIE INC. | AIRSUPRA, AREXVY, AUSTEDO XR, CREON, EVENITY, FREESTYLE LIBRE 3, INCEPTIV, JARDIANCE, KISUNLA, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error